HOME
HIV-HCV Coinfection
Hepatitis C
HIV and AIDS
Hepatitis B
HIV-HBV Coinfection
HIV-HCV Coinfection
HIV-related Immune Suppression Does Not Promote Genetic Divergence of Hepatitis C Virus in HIV-HCV Coinfected Individuals

One of the challenging features of the hepatitis C virus (HCV) is its rapid mutation rate, which helps it to escape immune system detection and enables it to quickly develop resistance to targeted antiviral drugs.

Some investigators have suggested that HIV-related immune suppression may alter interactions between the host and HCV, resulting in fewer amino acid substitutions in HCV viral variants. A group of researchers from Johns Hopkins University and Montefiore Medical Center tested this hypothesis in a study published September 2, 2008 in the online edition of the Journal of Acquired Immune Deficiency Syndromes.

Higher HCV RNA levels in HIV-HCV coinfected individuals compared to those with HCV infection alone suggest increased viral replication, the authors noted as background. If this increase is dependent on decreased selective pressure from a weakened immune system, then a reduced rate of viral nucleotide changes would be expected.

The study authors analyzed HCV envelope sequences over time from 79 chronic hepatitis C patients who were HIV negative, HIV positive without advanced disease, or HIV positive with severe immune deficiency.

They amplified and performed direct sequence analysis on a 1026-nt region of the HCV genome, which encodes a portion of the envelope glycoproteins E1 and E2, including hypervariable region-1.

They found that the overall divergence between the paired sequences dS, dN, and dN/dS all showed no significant differences among the 3 groups. There was no observed difference between HIV positive and HIV negative individuals, nor between HIV positive patients with minimal or severe immune deficiency.

"By measuring nucleotide substitutions in HCV sequences over time," the study authors concluded, "we found no significant differences in the genetic divergence between HCV monoinfected control subjects and HIV-HCV coinfected subjects with various levels of immunodeficiency as measured by CD4 T-cell counts."

Departments of Medicine and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD; Departments of Medicine and Epidemiology & Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

9/19/08

Reference
DM Netski, Q Mao, SC Ray, and others. Genetic divergence of hepatitis C virus: the role of HIV-related immunosuppression. Journal of Acquired Immune Deficiency Syndromes. September 2, 2008 [Epub ahead of print].
(Abstract).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved Hepatitis C
Treatments

Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
-
Treatment Guidelines
-
Experimental Treatments

FDA-approved HIV and
AIDS Treatments

Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide Reverse
  
Transcriptase Inhibitors NRTIs

Fixed-dose Combinations

Entry / Fusion Inhibitors EIs
Integrase Inhibitors
-
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
-
Experimental Treatments